Since the approval of trastuzumab for ERBB2-positive tumors in 1998, targeted systemic therapy remains a paramount goal of drug discovery and clinical care for breast cancer treatment.20 PARP inhibitors represent one of the newer classes of targeted therapies for breast and other solid tumors. This evidence concerns the gene ERBB2 and breast carcinoma.